The HRs for BC-specific mortality and BMI among ER + and HER2- tumors were 1.14 (1.03–1.25) and 1.16 (1.01–1.33) respectively; nonetheless, the heterogeneity tests by the ER and HER2 status did not achieve statistical significance. The gene discussed is ERBB2; the disease is breast cancer.